Stoke Therapeutics (NASDAQ:STOK) PT Raised to $21.00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) had its price target hoisted by equities research analysts at Canaccord Genuity Group from $18.00 to $21.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 48.20% from the stock’s current price.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Stoke Therapeutics in a research report on Friday, February 16th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $14.17 on Tuesday. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The stock has a market capitalization of $632.69 million, a PE ratio of -5.98 and a beta of 0.68. The business’s 50-day moving average is $5.88 and its 200 day moving average is $4.95.

Insider Activity at Stoke Therapeutics

In related news, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,615 shares of company stock worth $212,852. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Ensign Peak Advisors Inc bought a new position in Stoke Therapeutics in the 1st quarter valued at $25,000. Point72 Hong Kong Ltd purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $27,000. Great West Life Assurance Co. Can raised its holdings in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares in the last quarter. Dorsey & Whitney Trust CO LLC purchased a new stake in shares of Stoke Therapeutics in the 3rd quarter worth approximately $43,000. Finally, UBS Group AG bought a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $47,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.